Jan 11, 2021 (Baystreet.ca via COMTEX) -- Johnson & Johnson /zigman2/quotes/201724570/composite JNJ -2.64% is expected to deliver preliminary late-stage trial results for its one-dose COVID vaccine candidate by the end of January. If its jab is proven to be safe and effective, the company aims to deliver at least one billion doses by the end of the year.
The J&J vaccine was developed by the company's Belgian unit, Janssen Pharmaceutica, and is based on viral adenovirus vector technology, the same approach used to create the University of Oxford-AstraZeneca vaccine. This type of shot is easier to scale up than those developed by Pfizer-BioNTech and Moderna which are based on messenger RNA technology.
Said one health care analyst last week: "The J&J vaccine is more like the AstraZeneca vaccine, but it uses only one dose. So we know this approach works (viral-vector) and it targets the spike protein. We know that target works too. But, we'll have to see what one dose does."
Morgan Stanley's health care team said in a research note published last week that J&J's vaccine offers "unique elements and efficacy could surprise to the upside relative to AstraZeneca driving confidence in pandemic response and market recovery."
The investment bank is confident in the safety profile of the vaccine given early trial data, "along with the prior success and safety profile demonstrated in their Ebola vaccine as well as in investigational use in HIV, RSV and Zika."
With J&J's technology, the vaccine is estimated to remain stable for at least three months at normal refrigerated temperatures so does not require new infrastructure to transport.
JNJ shares faded 44 cents to $160.48.
Is there a problem with this press release? Contact the source provider Comtex at email@example.com. You can also contact MarketWatch Customer Service via our Customer Center.